dc.contributor.author |
Neumann, Bjoern |
dc.contributor.author |
Foerster, Sarah |
dc.contributor.author |
Zhao, Chao |
dc.contributor.author |
Bodini, Benedetta |
dc.contributor.author |
Reich, Daniel S. |
dc.contributor.author |
Bergles, Dwight E. |
dc.contributor.author |
Káradóttir, Ragnhildur Þóra |
dc.contributor.author |
Lubetzki, Catherine |
dc.contributor.author |
Lairson, Luke L. |
dc.contributor.author |
Zalc, Bernard |
dc.contributor.author |
Stankoff, Bruno |
dc.contributor.author |
Franklin, Robin J.M. |
dc.date.accessioned |
2022-08-26T01:04:19Z |
dc.date.available |
2022-08-26T01:04:19Z |
dc.date.issued |
2020-05-07 |
dc.identifier.citation |
Neumann , B , Foerster , S , Zhao , C , Bodini , B , Reich , D S , Bergles , D E , Káradóttir , R Þ , Lubetzki , C , Lairson , L L , Zalc , B , Stankoff , B & Franklin , R J M 2020 , ' Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis ' , Cell Stem Cell , vol. 26 , no. 5 , pp. 617-619 . https://doi.org/10.1016/j.stem.2020.03.017 |
dc.identifier.issn |
1934-5909 |
dc.identifier.other |
43318775 |
dc.identifier.other |
7498963f-1ca4-4bac-8888-cc14294f2fac |
dc.identifier.other |
85084118366 |
dc.identifier.other |
32386552 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/3374 |
dc.description |
The authors acknowledge the following support: The UK Multiple Sclerosis Society (MS50 to R.T.K., C.Z., and R.J.M.F.), The Adelson Medical Research Foundation (D.S.R., D.E.B., and R.J.M.F.), Intramural Research Program of NINDS/NIH (D.S.R.), European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Program (771411 to R.T.K.), The Lister Institute (R.T.K.), and a core support grant from the Wellcome and MRC to the Wellcome-Medical Research Council Cambridge Stem Cell Institute (203151/Z/16/Z to R.T.K. and R.J.M.F.). Publisher Copyright: © 2020 Elsevier Inc. |
dc.description.abstract |
Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS. |
dc.format.extent |
3 |
dc.format.extent |
554761 |
dc.format.extent |
617-619 |
dc.language.iso |
en |
dc.relation |
info:eu-repo/grantAgreement/EC/H2020/771411 |
dc.relation.ispartofseries |
Cell Stem Cell; 26(5) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
MS sjúkdómur |
dc.subject |
Molecular Medicine |
dc.subject |
Genetics |
dc.subject |
Cell Biology |
dc.title |
Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
dc.description.version |
Peer reviewed |
dc.identifier.doi |
10.1016/j.stem.2020.03.017 |
dc.relation.url |
http://www.scopus.com/inward/record.url?scp=85084118366&partnerID=8YFLogxK |
dc.contributor.department |
Faculty of Medicine |